{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T01:24:20Z","timestamp":1783128260966,"version":"3.54.6"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T00:00:00Z","timestamp":1565654400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T00:00:00Z","timestamp":1565654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s10620-019-05787-0","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T06:02:46Z","timestamp":1565676166000},"page":"480-488","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma"],"prefix":"10.1007","volume":"65","author":[{"given":"Zhitao","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyi","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifeng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjun","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8879-0574","authenticated-orcid":false,"given":"Jiamei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,13]]},"reference":[{"key":"5787_CR1","doi-asserted-by":"publisher","first-page":"565","DOI":"10.5604\/01.3001.0010.0293","volume":"16","author":"P Chinchilla-Lopez","year":"2017","unstructured":"Chinchilla-Lopez P, Aguilar-Olivos NE, Garcia-Gomez J, et al. Prevalence, risk factors, and survival of patients with intrahepatic cholangiocarcinoma. Ann Hepatol. 2017;16:565\u2013568. \nhttps:\/\/doi.org\/10.5604\/01.3001.0010.0293\n\n.","journal-title":"Ann Hepatol"},{"key":"5787_CR2","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1159\/000444562","volume":"34","author":"D Hogdall","year":"2016","unstructured":"Hogdall D, O\u2019Rourke CJ, Taranta A, Oliveira DV, Andersen JB. Molecular pathogenesis and current therapy in intrahepatic cholangiocarcinoma. Dig Dis. 2016;34:440\u2013451. \nhttps:\/\/doi.org\/10.1159\/000444562\n\n.","journal-title":"Dig Dis"},{"key":"5787_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30289","author":"AE Sirica","year":"2018","unstructured":"Sirica AE, Gores GJ, Groopman JD, et al. Intrahepatic cholangiocarcinoma: continuing challenges and translational advances. Hepatology. 2018. \nhttps:\/\/doi.org\/10.1002\/hep.30289\n\n.","journal-title":"Hepatology"},{"key":"5787_CR4","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41598-018-36096-7","volume":"9","author":"Y Wang","year":"2019","unstructured":"Wang Y, Kim TH, Fouladdel S, et al. PD-L1 expression in circulating tumor cells increases during radio(chemo)therapy and indicates poor prognosis in non-small cell lung cancer. Sci Rep. 2019;9:566. \nhttps:\/\/doi.org\/10.1038\/s41598-018-36096-7\n\n.","journal-title":"Sci Rep"},{"key":"5787_CR5","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.3892\/ol.2018.9747","volume":"17","author":"C Jiang","year":"2019","unstructured":"Jiang C, Zhu Y, Tang S, et al. High PD-L1 expression is associated with a favorable prognosis in patients with esophageal squamous cell carcinoma undergoing postoperative adjuvant radiotherapy. Oncol Lett. 2019;17:1626\u20131634. \nhttps:\/\/doi.org\/10.3892\/ol.2018.9747\n\n.","journal-title":"Oncol Lett"},{"key":"5787_CR6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00432-018-2758-6","volume":"145","author":"X Han","year":"2019","unstructured":"Han X, Gu YK, Li SL, et al. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma. J Cancer Res Clin Oncol. 2019;145:303\u2013312. \nhttps:\/\/doi.org\/10.1007\/s00432-018-2758-6\n\n.","journal-title":"J Cancer Res Clin Oncol"},{"key":"5787_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14520","author":"Y Wu","year":"2018","unstructured":"Wu Y, Zhao T, Jia Z, et al. Polymorphism of the programmed death-ligand 1 gene is associated with its protein expression and prognosis in gastric cancer. J Gastroenterol Hepatol. 2018. \nhttps:\/\/doi.org\/10.1111\/jgh.14520\n\n.","journal-title":"J Gastroenterol Hepatol"},{"key":"5787_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.imlet.2017.02.006","volume":"184","author":"X Wang","year":"2017","unstructured":"Wang X, Yang L, Huang F, et al. Inflammatory cytokines IL-17 and TNF-alpha up-regulate PD-L1 expression in human prostate and colon cancer cells. Immunol Lett. 2017;184:7\u201314. \nhttps:\/\/doi.org\/10.1016\/j.imlet.2017.02.006\n\n.","journal-title":"Immunol Lett"},{"key":"5787_CR9","doi-asserted-by":"publisher","first-page":"17810","DOI":"10.1038\/s41598-017-18132-0","volume":"7","author":"JW Moon","year":"2017","unstructured":"Moon JW, Kong SK, Kim BS, et al. IFNgamma induces PD-L1 overexpression by JAK2\/STAT1\/IRF-1 signaling in EBV-positive gastric carcinoma. Sci Rep. 2017;7:17810. \nhttps:\/\/doi.org\/10.1038\/s41598-017-18132-0\n\n.","journal-title":"Sci Rep"},{"key":"5787_CR10","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-18-0118","author":"H Tsukamoto","year":"2018","unstructured":"Tsukamoto H, Fujieda K, Miyashita A, et al. Combined blockade of IL-6 and PD-1\/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment. Cancer Res. 2018. \nhttps:\/\/doi.org\/10.1158\/0008-5472.can-18-0118\n\n.","journal-title":"Cancer Res"},{"key":"5787_CR11","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.12659\/MSM.907439","volume":"24","author":"J Li","year":"2018","unstructured":"Li J, Xu J, Yan X, Jin K, Li W, Zhang R. Targeting interleukin-6 (IL-6) sensitizes anti-PD-L1 treatment in a colorectal cancer preclinical model. Med Sci Monit. 2018;24:5501\u20135508. \nhttps:\/\/doi.org\/10.12659\/MSM.907439\n\n.","journal-title":"Med Sci Monit"},{"key":"5787_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12135","author":"L Xu","year":"2017","unstructured":"Xu L, Chen X, Shen M, et al. Inhibition of IL-6-JAK\/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell mediated cytotoxicity via alteration of PD-L1\/NKG2D ligand levels. Mol Oncol. 2017. \nhttps:\/\/doi.org\/10.1002\/1878-0261.12135\n\n.","journal-title":"Mol Oncol"},{"key":"5787_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.ma1217-495r","author":"C Rolvering","year":"2018","unstructured":"Rolvering C, Zimmer AD, Ginolhac A, et al. The PD-L1- and IL6-mediated dampening of the IL27\/STAT1 anticancer responses are prevented by alpha-PD-L1 or alpha-IL6 antibodies. J Leukoc Biol. 2018. \nhttps:\/\/doi.org\/10.1002\/jlb.ma1217-495r\n\n.","journal-title":"J Leukoc Biol"},{"key":"5787_CR14","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1158\/1078-0432.CCR-18-0284","volume":"25","author":"X Song","year":"2019","unstructured":"Song X, Liu X, Wang H, et al. Combined CDK4\/6 and pan-mTOR inhibition is synergistic against intrahepatic cholangiocarcinoma. Clin Cancer Res. 2019;25:403\u2013413. \nhttps:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0284\n\n.","journal-title":"Clin Cancer Res"},{"key":"5787_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.semcancer.2017.04.015","volume":"48","author":"JS O\u2019Donnell","year":"2018","unstructured":"O\u2019Donnell JS, Massi D, Teng MWL, Mandala M. PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. Semin Cancer Biol. 2018;48:91\u2013103. \nhttps:\/\/doi.org\/10.1016\/j.semcancer.2017.04.015\n\n.","journal-title":"Semin Cancer Biol"},{"key":"5787_CR16","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-17-0537","author":"GP Hartley","year":"2018","unstructured":"Hartley GP, Chow L, Ammons DT, Wheat WH, Dow SW. Programmed cell death ligand 1 (PD-L1) signaling regulates macrophage proliferation and activation. Cancer Immunol Res. 2018. \nhttps:\/\/doi.org\/10.1158\/2326-6066.cir-17-0537\n\n.","journal-title":"Cancer Immunol Res"},{"key":"5787_CR17","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1159\/000480000","volume":"42","author":"L Chen","year":"2017","unstructured":"Chen L, Xiong Y, Li J, et al. PD-L1 expression promotes epithelial to mesenchymal transition in human esophageal cancer. Cell Physiol Biochem. 2017;42:2267\u20132280. \nhttps:\/\/doi.org\/10.1159\/000480000\n\n.","journal-title":"Cell Physiol Biochem"},{"key":"5787_CR18","doi-asserted-by":"publisher","first-page":"6964","DOI":"10.1158\/0008-5472.CAN-16-0258","volume":"76","author":"CA Clark","year":"2016","unstructured":"Clark CA, Gupta HB, Sareddy G, et al. Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma. Cancer Res. 2016;76:6964\u20136974. \nhttps:\/\/doi.org\/10.1158\/0008-5472.CAN-16-0258\n\n.","journal-title":"Cancer Res"},{"key":"5787_CR19","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.cell.2015.08.052","volume":"162","author":"S Kleffel","year":"2015","unstructured":"Kleffel S, Posch C, Barthel SR, et al. Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth S6. Cell. 2015;162:1242\u20131256. \nhttps:\/\/doi.org\/10.1016\/j.cell.2015.08.052\n\n.","journal-title":"Cell"},{"key":"5787_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31357","author":"Y Gao","year":"2018","unstructured":"Gao Y, Yang J, Cai Y, et al. IFN-gamma-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling. Int J Cancer. 2018. \nhttps:\/\/doi.org\/10.1002\/ijc.31357\n\n.","journal-title":"Int J Cancer"},{"key":"5787_CR21","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2018.36.15_suppl.e24119","author":"S Chandrasekaran","year":"2018","unstructured":"Chandrasekaran S, Sasaki M, Pollack BP. Interrogating PI3K to induce PD-L1 expression in oral carcinoma. J Clin Oncol. 2018. \nhttps:\/\/doi.org\/10.1200\/jco.2018.36.15_suppl.e24119\n\n.","journal-title":"J Clin Oncol"},{"key":"5787_CR22","doi-asserted-by":"publisher","first-page":"e1434468","DOI":"10.1080\/2162402X.2018.1434468","volume":"7","author":"L Derosa","year":"2018","unstructured":"Derosa L, Routy B, Kroemer G, Zitvogel L. The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1\/PD-L1. Oncoimmunology. 2018;7:e1434468. \nhttps:\/\/doi.org\/10.1080\/2162402X.2018.1434468\n\n.","journal-title":"Oncoimmunology"},{"key":"5787_CR23","doi-asserted-by":"publisher","first-page":"8951","DOI":"10.1038\/s41598-017-09444-2","volume":"7","author":"N Maekawa","year":"2017","unstructured":"Maekawa N, Konnai S, Takagi S, et al. A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma. Sci Rep. 2017;7:8951. \nhttps:\/\/doi.org\/10.1038\/s41598-017-09444-2\n\n.","journal-title":"Sci Rep"},{"key":"5787_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/14737140.2017.1286986","volume":"17","author":"R Addeo","year":"2017","unstructured":"Addeo R. A new frontier for targeted therapy in NSCLC: clinical efficacy of pembrolizumab in the inhibition of programmed cell death 1 (PD-1). Expert Rev Anticancer Ther. 2017;17:199\u2013201. \nhttps:\/\/doi.org\/10.1080\/14737140.2017.1286986\n\n.","journal-title":"Expert Rev Anticancer Ther"},{"key":"5787_CR25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13045-018-0589-1","volume":"11","author":"R Tremblay-LeMay","year":"2018","unstructured":"Tremblay-LeMay R, Rastgoo N, Chang H. Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1\/PD-L1 pathway. J Hematol Oncol. 2018;11:46. \nhttps:\/\/doi.org\/10.1186\/s13045-018-0589-1\n\n.","journal-title":"J Hematol Oncol"},{"key":"5787_CR26","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","volume":"48","author":"C Sun","year":"2018","unstructured":"Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48:434\u2013452. \nhttps:\/\/doi.org\/10.1016\/j.immuni.2018.03.014\n\n.","journal-title":"Immunity"},{"key":"5787_CR27","doi-asserted-by":"publisher","first-page":"375","DOI":"10.4049\/jimmunol.1701044","volume":"200","author":"MW LaFleur","year":"2018","unstructured":"LaFleur MW, Muroyama Y, Drake CG, Sharpe AH. Inhibitors of the PD-1 pathway in tumor therapy. J Immunol. 2018;200:375\u2013383. \nhttps:\/\/doi.org\/10.4049\/jimmunol.1701044\n\n.","journal-title":"J Immunol"},{"key":"5787_CR28","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.2147\/CMAR.S172719","volume":"10","author":"Y Zhu","year":"2018","unstructured":"Zhu Y, Wang XY, Zhang Y, et al. Programmed death ligand 1 expression in human intrahepatic cholangiocarcinoma and its association with prognosis and CD8(+) T-cell immune responses. Cancer Manag Res. 2018;10:4113\u20134123. \nhttps:\/\/doi.org\/10.2147\/CMAR.S172719\n\n.","journal-title":"Cancer Manag Res"},{"key":"5787_CR29","first-page":"452A-A","volume":"97","author":"T Ueno","year":"2017","unstructured":"Ueno T, Mitsuhashi T, Hatanaka Y, et al. Prognostic significance of PD-L1 expression in extrahepatic cholangiocarcinoma. Lab Investig. 2017;97:452A-A.","journal-title":"Lab Investig"},{"key":"5787_CR30","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.cellsig.2016.04.004","volume":"28","author":"J Pinno","year":"2016","unstructured":"Pinno J, Bongartz H, Klepsch O, et al. Interleukin-6 influences stress-signalling by reducing the expression of the mTOR-inhibitor REDD1 in a STAT3-dependent manner. Cell Signal. 2016;28:907\u2013916. \nhttps:\/\/doi.org\/10.1016\/j.cellsig.2016.04.004\n\n.","journal-title":"Cell Signal"},{"key":"5787_CR31","doi-asserted-by":"publisher","first-page":"21260","DOI":"10.1038\/srep21260","volume":"6","author":"F Liu","year":"2016","unstructured":"Liu F, Zhang W, Yang F, et al. Interleukin-6-stimulated progranulin expression contributes to the malignancy of hepatocellular carcinoma cells by activating mTOR signaling. Sci Rep. 2016;6:21260. \nhttps:\/\/doi.org\/10.1038\/srep21260\n\n.","journal-title":"Sci Rep"},{"key":"5787_CR32","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1007\/s00535-013-0891-1","volume":"49","author":"HY Kim","year":"2014","unstructured":"Kim HY, Jhun JY, Cho ML, et al. Interleukin-6 upregulates Th17 response via mTOR\/STAT3 pathway in acute-on-chronic hepatitis B liver failure. J Gastroenterol. 2014;49:1264\u20131273. \nhttps:\/\/doi.org\/10.1007\/s00535-013-0891-1\n\n.","journal-title":"J Gastroenterol"},{"key":"5787_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2017.12.003","volume":"116","author":"K Takada","year":"2018","unstructured":"Takada K, Toyokawa G, Tagawa T, et al. PD-L1 expression according to the EGFR status in primary lung adenocarcinoma. Lung Cancer. 2018;116:1\u20136. \nhttps:\/\/doi.org\/10.1016\/j.lungcan.2017.12.003\n\n.","journal-title":"Lung Cancer"},{"key":"5787_CR34","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1016\/j.bbadis.2018.03.002","volume":"1864","author":"XY Qiu","year":"2018","unstructured":"Qiu XY, Hu DX, Chen WQ, et al. PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras\/Erk\/EMT activation. Biochim Biophys Acta Mol Basis Dis. 2018;1864:1754\u20131769. \nhttps:\/\/doi.org\/10.1016\/j.bbadis.2018.03.002\n\n.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"5787_CR35","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.jaad.2018.05.016","volume":"79","author":"S Park","year":"2018","unstructured":"Park S, Cho S, Kim M, et al. Dermatofibrosarcoma protuberans: a retrospective study of clinicopathologic features and related Akt\/mTOR, STAT3, ERK, cyclin D1, and PD-L1 expression. J Am Acad Dermatol. 2018;79:843\u2013852. \nhttps:\/\/doi.org\/10.1016\/j.jaad.2018.05.016\n\n.","journal-title":"J Am Acad Dermatol"},{"key":"5787_CR36","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1186\/s12885-018-5021-2","volume":"18","author":"H Mou","year":"2018","unstructured":"Mou H, Yu L, Liao Q, et al. Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report. BMC Cancer. 2018;18:1105. \nhttps:\/\/doi.org\/10.1186\/s12885-018-5021-2\n\n.","journal-title":"BMC Cancer"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-019-05787-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-019-05787-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-019-05787-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T23:49:09Z","timestamp":1597189749000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-019-05787-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,13]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["5787"],"URL":"https:\/\/doi.org\/10.1007\/s10620-019-05787-0","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,13]]},"assertion":[{"value":"21 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}